46 results about "Toxoplasmas" patented technology

The invention discloses a toxoplasma gondii attenuated vaccine strain RH delta rop67 as well as a construction method and application thereof, and belongs to the technical field of parasitic disease prevention and control and biological product preparation. The attenuated vaccine strain is constructed by performing targeted knockout on the ROP67 gene in a toxoplasma gondii strain RH delta ku80 through a CRISPR / Cas9 mediated gene editing technology. Compared with a wild type strain, the attenuated vaccine strain shows remarkable attenuation characteristic and good immunogenicity. A test result shows that the attenuated vaccine strain can induce a host to generate specific immune response mainly based on cellular immunity, maintains a protection effect on toxoplasma gondii infection in a relatively long immune period, and has a protection effect on tachyzoite infection and a chronic infection stage of toxoplasma gondii strains with different virulence; the survival ability of a host to tachyzoite infection can be improved, and the formation level of cysts in tissues is reduced. The invention provides a technical scheme with long-term immune potential for research and development of toxoplasma gondii attenuated vaccines.

This invention discloses an antibody that specifically recognizes Toxoplasma gondii surface antigens and its applications. The invention utilizes hybridoma technology to establish a hybridoma cell line by fusing Balb / C mouse spleen cells with SP2 / 0 cells. Monoclonal antibodies were prepared from these cells using in vitro culture and in vivo ascites induction methods, yielding the monoclonal antibody SH12-S7. This invention provides clinical and research institutions with an antibody that specifically recognizes Toxoplasma gondii surface antigens. It can be used for ELISA assays to detect clinical samples, for immunohistochemical assays to diagnose pathological specimens, and provides a convenient research tool for toxoplasmosis research departments. It has broad application value in the diagnosis and detection of definitive host infections and provides technical support for epidemiological investigations and evaluation of control effects of Toxoplasma gondii.

The application discloses application of squaraine compounds in preparation of anti-toxoplasmosis drugs. The application provides a new application of squaraine compounds in anti-toxoplasma infection. Through synthesis of squaraine compounds and insect inhibiting experiments, two preferred squaraine compounds, F-squaraine and 3-F-squaraine, with better insect inhibiting effects are found. The two preferred squaraine compounds have higher in-vitro insect inhibiting rates on toxoplasma, can well inhibit in-vitro replication of toxoplasma, significantly inhibit formation of insect plaques, and can effectively inhibit growth of toxoplasma. The two preferred squaraine compounds have good safety and do not have cytotoxicity, and belong to squaraine compounds with low toxicity or no toxicity. Meanwhile, the squaraine compounds provided by the application can also inhibit reproduction of toxoplasma in mice, treat toxoplasmosis, have significant treatment effects, and will not affect growth of the mice. The squaraine compounds can be used for resisting toxoplasma infection, and can be used for preparing and developing more products for resisting toxoplasma infection and drugs for treating toxoplasmosis. The squaraine compounds have important significance for research and development of drugs for treating toxoplasmosis.

The invention relates to the technical field of medicinal chemistry and parasitic disease prevention and treatment, and particularly discloses a novel harmine derivative, a synthesis method and application of the novel harmine derivative to toxoplasma gondii disease resistance. The structural general formula of the derivative is shown in the specification. Wherein R1 is selected from one of hydrogen, C1-4 alkyl, substituted or non-substituted five-membered aryl or six-membered aryl, and substituted or non-substituted five-membered heteroaryl or six-membered heteroaryl containing 1 to 4 heteroatoms selected from N, O or S; r9 is selected from one of hydrogen, substituted or unsubstituted five-membered aryl or six-membered aryl; and R7 is selected from hydrogen, C1-4 alkyl, substituted or unsubstituted five-membered aryl or six-membered aryl. Preferably, the compound is 1-methyl-9-(3-methylpyridine)-beta-carboline-7-ol, and the formula is shown in the description. The novel harmine derivative provided by the invention shows high-efficiency and low-toxicity anti-toxoplasma gondii activity, the synthesis method is simple, and an excellent candidate compound is provided for developing novel anti-toxoplasma gondii drugs.

The invention belongs to the field of toxoplasma gondii prevention and control, and particularly relates to an anti-toxoplasma gondii small molecule compound and application thereof. The small molecule compound is shown as a formula 1. The small molecule compound provided by the invention can inhibit growth, invasion and intracellular replication of toxoplasma gondii.

The invention discloses a toxoplasma gondii gene deletion strain ME49 [delta] TGZS and an application thereof in preparation of a gene engineering inactivated vaccine. The toxoplasma gondii gene deletion strain ME49 [delta] TGZS is prepared by taking a toxoplasma gondii strain ME49 as a parent strain and knocking out a TGZS gene in the toxoplasma gondii strain ME49; the nucleotide sequence of the TGZS gene is as shown in SEQ ID NO: 1. The strain can maintain normal polypide growth and replication capacity under an in-vitro culture condition, after inactivation treatment, the strain loses proliferative activity but maintains a complete polypide morphological structure, and the strain is compatible with an aluminum hydroxide adjuvant to prepare a vaccine preparation. According to the vaccine, by activating the specific immune response of a terminal host cat, the sexual reproduction cycle of the toxoplasma gondii in the intestinal epithelial cells of the cat is effectively blocked, and the formation and discharge of oocysts are remarkably inhibited, so that the propagation chain of the toxoplasma gondii is controlled from the source. The invention provides a new effective means for prevention and control of toxoplasmosis.

The invention discloses an application of docetaxel in preparation of drugs for resisting toxoplasmosis, and belongs to the technical field of medicines. Through a series of experimental studies, it is found that docetaxel can significantly delay the onset time of mice infected with toxoplasma gondii virulent strains and effectively reduce the death rate of mice infected with toxoplasma gondii attenuated strains. Docetaxel shows a relatively strong inhibition effect in the aspect of treating related diseases caused by a virulent strain or a low virulent strain of toxoplasma gondii, and can effectively slow down the infection process and prolong the life cycle of a host. In combination with in-vitro cell experiment and in-vivo animal experiment results, the taxane drug has a good treatment prospect, can be used as a development basis of a novel toxoplasmosis-resistant drug, and promotes the realization of a novel treatment scheme.

The invention discloses application of a toxoplasma gondii gene deletion strain for expressing a tumor specific antigen receptor in preparation of an anti-tumor biological preparation. The toxoplasma gondii gene deletion strain (CAR-Tg) for expressing a tumor specific antigen receptor is used for resisting tumors, and particularly, the thought and strategy for treating solid tumors have obvious advantages and innovations, so that the toxoplasma gondii gene deletion strain is a positive application for resisting tumors of toxoplasma gondii; compared with a CAR-T therapy method, the CAR-Tg strain for anti-tumor therapy can effectively overcome the defects that the treatment effects of individualized customization, time and labor waste, insufficient T cell infiltration, depletion and the like are limited, potential carcinogenic risks exist and the like, and has remarkable gain and effects; the CAR-Tg strain expresses a tumor specific antigen receptor on the basis of a toxoplasma gondii gene deletion strain, the targeted tumor killing capacity of toxoplasma gondii can be improved, the anti-tumor effect is improved, and the anti-tumor effect can be improved when the CAR-Tg strain is combined with an anti-tumor drug such as a small-molecule inhibitor.

This invention discloses a live attenuated vaccine for the prevention of Toxoplasma gondii infection, the active ingredient of which is the tachyzoite of the Toxoplasma gondii RHΔpCaBp1 gene knockout strain. This invention prepares a live attenuated RHΔpCaBp1 vaccine that can be used to prevent Toxoplasma gondii infection in intermediate hosts. Immunization with this live attenuated vaccine, containing 100 Toxoplasma gondii RHΔpCaBp1 tachyzoites, via intraperitoneal injection, showed safety in mice after three immunizations, and demonstrated 100% protection against low-dose virulent strains (intraperitoneal injection of 100 and 500 RH tachyzoites) in the model intermediate host.

To provide a new serum marker whose expression is restricted to the latent form of toxoplasmosis (bradyzoites / cysts). Also provided is an antibody that specifically binds to the new protein.SOLUTION: The present invention relates to a new Toxoplasma gondii protein, hereinafter referred to as BCLA, a new serum marker whose expression is restricted to the latent form of toxoplasmosis. This specific protein and its antigenic fragments can be used to detect autoantibodies in the serum of patients for the diagnosis of latent forms of toxoplasmosis. The invention also relates to derived antibodies generated by BCLA immunization that specifically bind to this new protein.SELECTED DRAWING: None

The invention discloses a double PCR (Polymerase Chain Reaction) detection kit for trichina and toxoplasma gondii and application of the double PCR detection kit. The kit comprises upstream and downstream primer pairs for detecting trichina and toxoplasma gondii respectively, 2 * Taq Master Mix and non-enzyme water, the primer pair for detecting the trichina specifically aims at a complete sequence of a trichina T1 isolate ISS 003 ribosome small subunit gene, and the primer pair for detecting the toxoplasma gondii specifically aims at a toxoplasma gondii H66R isolate 529REP repetitive sequence region. The duplex PCR detection system disclosed by the invention is good in specificity, and does not generate cross reaction with other common polypide bodies; corresponding target fragments can be amplified when trichina and toxoplasma gondii are detected, and no amplified fragment appears when common pig parasites are detected, so that the specificity is high; the detection limit is 0.10 ng / mu L, so that the kit has relatively high sensitivity. In conclusion, the detection kit disclosed by the invention is high in sensitivity, strong in specificity, mild in reaction condition, short in reaction period and high in detection flux, and can be used for rapidly screening the toxoplasma gondii and trichina in meat products and live pigs in various scenes.

This invention discloses the construction of a Toxoplasma gondii progesterone-responsive kinase-deficient strain and its application as a live attenuated vaccine. The Toxoplasma gondii progesterone-responsive kinase-deficient strain is derived from Toxoplasma gondii RHΔ... ku80 As a maternal strain, the gene-editing technology was used to knock out the enzyme encoding progesterone-responsive kinase. prk The gene-deleted strain was named RHΔ ku80 Δ prk Experiments have shown that RHΔ ku80 Δ prk The virulence of the strain was significantly reduced, and immunized mice showed good immunoprotection against acute infection with highly virulent and moderately virulent Toxoplasma gondii strains, and significantly inhibited brain cyst formation in a chronic infection model. Therefore, RHΔ ku80 Δ prk This invention has potential application value as a live attenuated vaccine against Toxoplasma gondii. It has significant application prospects.

The application discloses a preparation method of a functionalized taper thin-core micro-nano optical fiber, a product of the functionalized taper thin-core micro-nano optical fiber and a method for detecting toxoplasma antibodies. The functionalized taper thin-core micro-nano optical fiber is hydroxylated and silanized in a sensing area, and then is modified by MoS2. The MoS2 has the advantages of high electron mobility, a large surface-to-volume ratio and existing self-thiol groups. More to-be-detected substances can be fixed, and the functionalized taper thin-core micro-nano optical fiber is widely applied in biosensors. The application establishes an antibody detection method with high sensitivity and strong specificity.

The invention discloses application of a compound triclosan in preparation of a medicine for treating toxoplasmosis. The medicine is used for inhibiting toxoplasmosis proliferation. The medicine is used for relieving pathological injuries of one or more organs caused by toxoplasma gondii infection, and the organs comprise the heart, the liver, the spleen, the kidney and the brain. The medicine is used for protecting brain tissues or penetrating a blood brain barrier to treat toxoplasma gondii infection of a central nervous system; the medicine comprises a therapeutically effective amount of triclosan and a pharmaceutically acceptable carrier or auxiliary material, the dosage form of the medicine is an oral preparation; the application has the beneficial effects that the broad-spectrum antibacterial agent triclosan is proved to have a new application of remarkably treating toxoplasmosis for the first time, in-vivo and in-vitro experiments prove that triclosan can effectively inhibit the proliferation of toxoplasmosis, the effect is dose-dependent, and in an acute infection mouse model, triclosan can remarkably improve the survival rate of mice and reduce the ascites insect-bearing quantity, so that the effect of treating toxoplasmosis is achieved. The pathological injury of multiple organs such as heart, liver, spleen and kidney can be relieved.

The utility model relates to the technical field of filter elements, in particular to a toxoplasma gondii intercepting filter element containing a nano-antibacterial coating, which comprises a shell and an adaptive cover plate, a water inlet pipe and a water outlet pipe are arranged on the outer side of the shell, a limiting piece attached to the bottom of the cover plate is arranged in the shell, and the nano-antibacterial coating is arranged in the limiting piece. A plurality of annularly-distributed inner clamping grooves are formed in the inner side wall of the shell, a partition plate is fixed between one inner clamping groove and the limiting piece, and the water inlet pipe and the water outlet pipe are located on the two sides of the joint of the partition plate and the shell correspondingly; according to the utility model, the antibacterial filter materials can be clamped between the limiting piece and the inner clamping groove of the shell, so that the installation work of different numbers of antibacterial filter materials can be carried out according to the installation requirements; and the filter material unit can be conveniently and quickly replaced after the cover plate is opened in the later period.

The invention provides a polypeptide and application thereof in preparation of a toxoplasma gondii infection resistant product. The amino acid sequence of the polypeptide is shown as SEQ ID NO: 1. The polypeptide provided by the invention has the obvious advantage of multi-dimensional synergistic toxoplasma gondii infection resistance, can effectively inhibit growth and reproduction of toxoplasma gondii in vitro and in vivo, reduce the polypide load of a host, relieve excessive inflammation caused by infection, promote damage repair of tissues including intestinal tracts, and contribute to improvement of intestinal flora balance. The invention provides a new technical strategy for developing a safe and comprehensive toxoplasma gondii infection prevention and treatment and prognosis improvement anti-toxoplasma gondii product in the field, and has popularization and application values.

Belonging to the field of genetic engineering, a recombinant Toxoplasma gondii vaccine having undergone gene deletion and a construction method therefor are provided. Specifically, a recombinant Toxoplasma gondii strain having undergone gene deletion, a medicament and / or biological product containing same, a construction method, and a use thereof are provided. A live attenuated toxoplasmosis vaccine developed on the basis of the recombinant Toxoplasma gondii strain is suitable for immunoprophylaxis of toxoplasmosis in various mammals, can block transmission of toxoplasmosis to humans and other animals, and is particularly suitable for immunoprophylaxis of feline Toxoplasma gondii infection and / or toxoplasmosis. The provided vaccine is easy to produce, is high in safety, has excellent efficacy, has long immune duration, is capable of distinguishing vaccine immunization from natural infection, does not harm animals or the environment, is capable of effectively reducing residual Toxoplasma oocysts in the environment, and is capable of reducing the risk of human infection with toxoplasmosis.

The invention relates to the field of toxoplasma gondii detection, and discloses a toxoplasma gondii IgM antibody detection test strip, which comprises a substrate, a sample loading pad, a colloidal gold adsorption pad marked with a C line, a colloidal gold adsorption pad marked with a T line, and a water absorption pad, a sample loading pad, a colloidal gold adsorption pad marked with a C line, a colloidal gold adsorption pad marked with a T line, a nitrocellulose membrane and a water absorption pad are sequentially arranged on the substrate along the liquid chromatography direction; the solid-phase colloidal gold T line is labeled with a TOX recombinant antigen, and the solid-phase colloidal gold C line is labeled with a mouse monoclonal antibody; the nitrocellulose membrane is sequentially coated with a detection line and a quality control line; the detection line is coated with an anti-human IgM chain monoclonal antibody, and the quality control line is coated with an anti-mouse IgG polyclonal antibody; the test strip has the technical advantages of high sensitivity and high specificity, few types of raw materials are used, the use amount is low, the production cost is effectively controlled, the quantity of samples required for detection is extremely small, the efficiency is high, special instruments are not needed, direct judgment can be carried out through naked eyes, and the operation is more convenient and efficient.

The application discloses application of a Toxoplasma gondii TGME49_229320 protein in preparation of a Toxoplasma gondii diagnosis kit, a nucleotide sequence of a coding gene of the Toxoplasma gondii TGME49_229320 protein is shown as SEQ ID NO:1, and the application further discloses a Toxoplasma gondii diagnosis kit and an indirect ELISA method for detecting Toxoplasma gondii for non-diagnosis purposes, and belongs to the field of molecular biology.The application provides more candidate antigens for pathogen detection and prevention and control of Toxoplasma gondii, and the established method can specifically detect antibody serum of Toxoplasma gondii oocyst infection, and has the advantages of good accuracy, strong sensitivity and the like.

The invention discloses a construction method and application of a toxoplasma gondii RH delta cenl1 attenuated vaccine strain, and belongs to the technical field of vaccine preparation. A CENL1 gene is knocked out from an RH delta ku80 strain through CRISPR / Cas9 mediated gene editing, so that a toxoplasma gondii RH delta cenl1 attenuated vaccine strain is obtained. The attenuated vaccine strain is a toxoplasma gondii live vaccine candidate strain with an attenuated characteristic, shows significantly reduced toxicity in a mouse body, and can induce the body to generate strong immune response mainly including Th1 type. Immune protection evaluation results show that mice surviving after primary immunization of RH delta cenl1 do not show a complete protection effect after being infected again by the high-toxicity RH strain, but the survival time of the immunized mice can be remarkably prolonged, the disease progress can be slowed down, and certain immune protection potential is shown. The invention provides an important experimental basis for screening of toxoplasma gondii attenuated live vaccines and optimization of immune prevention and control strategies.

The invention belongs to the technical field of gene engineering, and particularly relates to a toxoplasma gondii attenuated strain as well as a construction method and application thereof. The invention relates to a construction method of a toxoplasma gondii DDX6 gene deleted strain. The toxoplasma gondii DDX6 gene deleted strain is obtained by knocking out a TgDDX6 gene. Wherein the sequence of the TgDDX6 gene is Gene ID: TGGT1313010, and the updating date of the TgDDX6 gene is November 5, 2020. The delta DDX6 immunization has a remarkable immune protection effect on bad pregnancy caused by toxoplasma gondii infection during pregnancy, and can maintain normal states of uterus and placenta to a certain extent, promote normal development of a fetus, reduce the stillbirth rate and relieve negative effects of toxoplasma gondii infection on the pregnancy process and the fetus; a good protection effect is also achieved on acute and chronic toxoplasma gondii infection.

This invention provides a droplet-based digital PCR primer-probe set for detecting *Toxoplasma gondii* and its applications, belonging to the field of molecular biology. This invention targets the conserved region of the *Toxoplasma gondii* SAG1 gene, designing and screening a specific primer-probe set. The forward primer sequence is shown in SEQ ID NO:1, the reverse primer sequence in SEQ ID NO:2, and the probe sequence in SEQ ID NO:3. This invention constructs a reaction system with the nucleic acid of the sample to be tested, the primer-probe set, and a PCR premix. After dropletization or loading onto a digital PCR chip, amplification is performed, and absolute quantification is achieved through positive droplet counting and Poisson distribution. The detection method of this invention has high sensitivity, strong specificity, and good repeatability. This invention provides an efficient and reliable technical means for the early diagnosis, detection of low-load samples, and quantitative monitoring of *Toxoplasma gondii* infection.

The invention relates to the technical field of gene engineering, and particularly discloses a toxoplasma gondii Me49 BFD2 PDX1 strain as well as a construction method and application thereof, and the toxoplasma gondii Me49 BFD2 PDX1 strain is obtained by knocking out a PDX1 gene in a Me49 BFD2 strain through a gene editing means. The toxoplasma gondii Me49 BFD2 PDX1 strain tachyzoite provided by the invention is used for inhibiting the growth of tumor cells and reducing the volume and the mass of tumors after being inactivated.

The invention is suitable for the technical field of computational biology and parasitic molecule epidemiology, and provides a whole genome machine learning method and system for toxoplasma gondii population structure analysis. According to the method, an SNP genotype probability matrix is constructed by using whole genome sequencing data, an optimal group structure is identified in combination with unsupervised clustering, and then multi-site sequence typing and rapid classification prediction of toxoplasma gondii are realized through supervised tag integration and supervised learning models. According to the method, a closed-loop mechanism of'unsupervised clustering-semi-supervised labeling-supervised learning 'is formed, and interpretability and expandability are achieved while high precision (the average accuracy is about 97%) is kept. According to the method, core information sites are obtained through screening based on progressive feature selection of feature importance, high robustness and accuracy can still be kept under the background of low sequencing depth and metagenome mixing, support is provided for genetic differentiation evaluation, epidemiological traceability and the like, modules are clear and easy to integrate, and efficient landing is achieved.

In this invention, the inventors report the characterization of BCLA (brain cyst-loaded antigen), a protein uniquely expressed in the merozoite stage of a parasite. In cysts directly purified from mouse brain, the protein is distributed both internally and on the surface of the cyst. ELISA antibody capture using a combination of serologically reactive BCLA peptide and recombinantly expressed C-terminal domain (rBCLA) constitutes an effective serological marker of latent infection with high sensitivity, definitively and uniquely correlated with the presence of cysts in mouse brain. Antibodies against the BCLA antigen have been detected in human patients. Enrichment titers were detected in patients identified as seropositive for Sag1 or tachyzoite-associated antigen. Further correlation between anti-BCLA IgG synthesis and cysts in humans was demonstrated by significantly stronger recorded titers in the pathology group strongly correlated with the presence of cysts. Furthermore, newborns with confirmed congenital toxoplasmosis showed significantly higher levels of anti-BCLA IgG at birth compared to their mothers, indicating specific intrauterine synthesis of this IgG. Therefore, this invention relates to a novel Toxoplasma gondii protein, hereinafter referred to as BCLA, which is a novel serological marker whose expression is limited to latent toxoplasmosis (schizonts / cysts). This specific protein and its antigenic fragments can be used to detect autoantibodies in patient serum for the diagnosis of latent toxoplasmosis. This invention also relates to derived antibodies that specifically bind to this novel protein, generated through immunization with BCLA.

The invention relates to an application of TLR < 4 > siRNA (TLR < 4 > siRNA (at) LNP-CSA-BP) coated with TLR < 4 > siRNA (TLR < 4 > siRNA) connected with placental Chondroitin sulfate A binding peptide (Placental Chondroitin sulfate A binding peptide, CSA-BP) injected in a maternal pregnancy period, in improvement of pregnancy complications and prevention of progeny neurodevelopment disorder diseases, in particular to an application of TLR < 4 > siRNA coated with LNP-CSA-BP coated with TLR < 4 > siRNA coated with LNP-CSA-BP. According to the invention, TLR4siRNA (at) LNP-CSA-BP is used for carrying out caudal vein injection on a pregnant mouse, so that a placenta and fetal brain inflammation microenvironment (induced by toxoplasma gondii STAg) maternal immune activation can be inhibited. Behavior experiments further prove that under a maternal immune activation model, TLR4siRNA (at) LNP-CSA-BP caudal vein injection pregnant mice can significantly improve phenotypes of neurodevelopmental disorder diseases of filial generation mice, such as core symptoms (social ability and repeated engraving behaviors) of autism behaviors, and the promising transformation prospect is proved.

The application belongs to the technical field of medicine preparation, and particularly relates to application of Irisolidon B in preparation of medicine for preventing and / or treating toxoplasma infection. The application utilizes Irisolidon B to inhibit toxoplasma GFP-RH, and it is found through experiments that 0.025-1.6 muM of Irisolidon B has a significant inhibitory effect on the proliferation of toxoplasma GFP-RH in SH-SY5Y cells. The half inhibitory concentration (EC 50 ) of Irisolidon B on toxoplasma GFP-RH is 0.25 muM. The application provides a potential drug target for the treatment or prevention of toxoplasmosis.

The invention discloses a toxoplasma gondii CTL epitope peptide identification method and application. The toxoplasma gondii CTL epitope peptide identification method comprises the following steps: constructing a toxoplasma gondii infection model of an HLA-A * 0201 transgenic mouse; capturing a natural peptide fragment combined with the HLA-A * 0201 molecule from the spleen lymphocyte surface of the infected model mouse through a weak acid elution method; analyzing the captured peptide fragment by adopting a liquid chromatography-tandem mass spectrometry technology, and screening a toxoplasma gondii-sourced specific peptide fragment based on a toxoplasma gondii protein database; through an in-vitro protein renaturation experiment, the binding capacity of the screened candidate peptide fragment and the HLA-A * 0201 molecule is verified; a TAP defect type T2 lymphoblastic cell model is adopted, and the binding stability of the candidate peptide fragment and the HLA-A * 0201 molecule is verified through a fluorescence index. According to the method, through a progressive screening strategy that after natural peptide group screening, a NetMHCpan-4.1 algorithm is adopted for filtering and eliminating host homology, in-vitro pMHC-I renaturation verification and T2 cell binding stability detection are carried out, the clinical transformation value of epitope screening is remarkably improved, and high-confidence candidate molecules are provided for toxoplasma gondii multi-epitope vaccine design.

The invention discloses a traditional Chinese medicine preparation for preventing and treating toxoplasma gondii and a preparation method, and belongs to the technical field of traditional Chinese medicines. The composition is prepared from pure herbal medicines, the medicine cost is low, the composition is suitable for industrial production, the mixture prepared from the pure herbal medicines can effectively detect toxoplasma gondii, and the detection effective rate reaches 100%; meanwhile, parameters of each step are accurately controlled, so that all the components have a synergistic effect on physical and chemical levels. In the drying step, moisture in the raw materials is removed, microbial contamination is avoided, and the subsequent processing efficiency is improved. The crushing step refines the raw materials to a specific particle size, increases the surface area, and improves the extraction rate of effective components. The decocting step is carried out at a specific temperature, so that the effective components of all the components are fully dissolved and have chemical reaction, and active substances with the effect of expelling toxoplasma gondii are generated. Impurities are further removed in the percolation step, the purity and stability of final liquid medicine are guaranteed, and prevention, treatment, detection, expelling and killing of toxoplasma gondii are effectively achieved.

The invention discloses a recombinant protein Sex-Ag-1 and an application of the recombinant protein Sex-Ag-1 in preparation of a cat toxoplasma gondii subunit vaccine. The high-purity recombinant protein is obtained by screening a coding gene of a specific antigen Sex-Ag-1 in a sexual reproduction stage of toxoplasma gondii, cloning the coding gene to a prokaryotic expression vector, and performing induced expression and purification. The protein can be used for preparing a toxoplasma gondii subunit vaccine for cats, and the formation and discharge of toxoplasma gondii oocysts are blocked by immunizing felines to excite specific immune response, so that the diffusion of toxoplasmosis is controlled from a transmission source. The vaccine has the characteristics of strong targeting property, high safety, stable immune effect and the like, and a new technical scheme is provided for solving the problems that the existing toxoplasmosis prevention and control traditional Chinese medicine treatment is limited, effective vaccines are lacked and the like.